No Data
Kewell Bio (301301.SZ): Will gradually release the production capacity of the synthetic biology base this year.
On February 25, Glonghui reported that Chuan Ning Biotechnology (301301.SZ) stated on the investor interaction platform that the company will gradually release the production capacity of the synthetic biology base this year, and its revenue share will also increase.
Is Yili Chuanning BiotechnologyLtd (SZSE:301301) Using Too Much Debt?
Chuan Ning Biology: Yili Chuanning Biotechnology Co., Ltd. 2024 Annual Performance Forecast
Is Yili Chuanning Biotechnology Co.,Ltd.'s (SZSE:301301) Latest Stock Performance Being Led By Its Strong Fundamentals?
Chuaning Bio (301301.SZ): Plans to postpone the "Shanghai Research Institute Construction Project" to December 31, 2025.
On December 19, 2023, Gelonghui reported that Chuaning Biological (301301.SZ) held the eighth meeting of its second Board of Directors and the seventh meeting of its second Supervisory Board, which approved the proposal concerning the extension of fundraising investment projects. The company agreed to adjust the deadline for the "Shanghai Research Institute Construction Project" to reach the predetermined usable status to December 31, 2025, without changing the total investment amount, implementing subject, or content of the fundraising projects.
Crown Bio (301301.SZ): Research and development investment mainly in the synthetic biology Sector.
On December 16, Gelonghui reported that Chuan Ning Biological (301301.SZ) stated on the investor interaction platform that the company's research and development expenses in the first three quarters of 2024 amounted to 44.0661 million yuan, an increase of 12.82% year-on-year, with a continuous growth in R&D expenses. The main reason for the relatively low proportion of total revenue is that the company's revenue is growing rapidly; the company's R&D investment is mainly in the synthetic biology Sector, which has a relatively high overall R&D input-output ratio.